Dr. Hong founded our company in 1997 and has served as Chairman of the board of directors since January 2002 and Chief Executive Officer since January 2005. Prior being our CEO, Dr. Hong was our Science and Technology Adviser from 1997 to 2004. Dr. Hong co-founded Hermes Biosciences, Inc. and served as its Chief Scientific Officer from 1999 to 2005. Before venturing into the world of drug development, Dr. Hong served as Research Scientist for the California Pacific Medical Center Research Institute from 1998 to 2002. Prior to that, Dr. Hong was a Scientist at the Liposome Research Laboratory at the Cancer Research Institute of the University of California, San Francisco from 1979 to 1998. Dr. Hong has served as a consultant to various biopharmaceutical companies over the years.
Dr. Hong received a Ph.D. in Chemistry from the University of California, Berkeley, an M.S. in Chemistry from the University of Texas at El Paso, and a B.S. in Chemistry from Taiwan Cheng Kung University.
Taiwan Global Biofund has served as a member of our board of directors since June 2007. Dr. Chang has served as Taiwan Global Biofund’s representative to our board of directors since June 2007. Dr. Chang is the Chief Executive Officer and President of Taiwan Global Biofund, a venture capital fund, as well as the Chairman and Chief Executive Officer of YFY Biotech Management Company, a biotechnology consulting firm. He has held both positions since 2005. Dr. Chang serves as director to several publicly traded companies on the TPEx, including Excelsior Biopharma Inc., Taigen Biopharmaceuticals Holdings Limited, Mycenax Biotech Inc. and Twi Biotechnology, Inc., all of which are biopharmaceutical companies. Dr. Chang served at the Taiwan Department of Health as Deputy Minister from June 2004 to October 2004, as President and Chief Executive Officer of the Bureau of National Health Insurance from 2001 to 2004, and Director General of the Center of Disease Control from 1999 to 2000.
Dr. Chang received an M.D. from National Yang-Ming Medical College, an M.S. in Public Health from National Taiwan University, and an M.S. of Health Policy and Management from the Harvard School of Public Health.
Burrill Life Sciences Capital Fund III, L.P. has served as a member of our board of directors since June 2009. Dr. Dalal has served as Burrill Life Sciences Capital Fund III, L.P.’s representative to our board of directors since September 2017. is currently Chief Investment Officer at Acuta Capital Partners, LLC, an investment management services firm. Prior to joining Acuta Capital Partners, LLC in August 2016, Dr. Dalal was the Managing Director of Kearny Venture Partners, a healthcare investment firm, from 2006 to July 2016. Dr. Dalal founded and was a managing member of KVP Capital GP, LLC, a venture capital firm, from April 2013 to July 2016, and was a principal at Flagship Pioneering, a private equity and venture capital firm, from 2002 to 2006. Dr. Dalal also serves on the board of directors of Aerpio Pharmaceuticals, Inc. (formerly Aerpio Therapeutics, Inc.), a publicly traded biopharmaceutical company.
Dr. Dalal received an M.D. from the University of California, San Francisco, an M.B.A. from Harvard Business School, and a B.A. in Economics from the University of California, Berkeley.
Chang Xiang Investment Company, Ltd. has served as a member of our board of directors since June 2014. Mr. Lee has served as Chang Xiang Investment Company, Ltd.’s representative to our board of directors since June 2014. Prior to that, Mr. Lee was self employed in financial investments from April 2012 to May 2014.
Mr. Lee received an M.S. in Actuarial Science from the University of Iowa. Mr. Lee has an M.S. in Finance from Seattle University and a B.A. from Tamkang University in Taiwan.
Mr. Lin has served as a member of our board of directors since May 2017. Mr. Lin is the Chairman at Nan Hsin Investment Limited Company, an investment firm, where he has held the position since 2001. Prior to that, Mr. Lin served as President of H&Q Taiwan Co., Ltd., an investment firm, from 1995 to 1999, whilst concurrently serving as a managing director of H&Q Asia Pacific, a private equity firm and the parent company of H&Q Taiwan Co., Ltd. From 1987 to 1995, Mr. Lin served in various investment positions from manager to vice president at H&Q Taiwan Co., Ltd.
Mr. Lin received an M.B.A from National Chiao Tung University and a B.S. degree from National Taiwan University.
Dr. Liu has served as a member of our board of directors since June 2011. Dr. Liu is currently a partner at BDO Taiwan, an accounting firm, where she has held the position since August 1991. Dr. Liu is also the director at Genovate Biotechnology Co., Ltd., where she has held the position since June 2017. Dr. Liu also serves as the director of the National Federation of Certified Public Accountants Association, ROC and is a member of the American Institute of Certified Public Accounts.
Dr. Liu received a Ph.D. in Accounting from Xiamen University, an M.A. in Accounting from the University of Illinois at Urbana-Champaign, and a B.S. in Taxation from National Cheng-Chi University.
Ms. Kang has served as a member of our board of directors since 2012. Ms. Kang is currently the Chairman at Fun-I Investment Co., where she has held the position since 2012. Ms. Kang served as Chief Executive Officer of IF Technology Company Co. from November 2013 to December 2016. Prior to that, Ms. Kang served as the general manager at Waterland Securities Co. Ltd, a brokerage company, from 2006 to 2011. Before that, Ms. Kang served as Vice President at Yuanta SITC (Yuanta Funds), an asset management company, from 2002 to 2006, and as Chief Investment Officer with Yuanta Securities Co. Ltd., a finance service company, from 1993 to 2006.
Ms. Kang received an M.B.A. from National Taiwan University, and a B.Com. in International Trade from National Taiwan University.
Dr. Tom Chen has served as a member of our board of directors since May 2017. He served as vice president at Optimer Biotechnology Inc. from 2005 until he retired in October 2009. Prior to that, Dr. Tom Chen served as the head of the drug development program at the Development Center for Biotechnology in Taiwan from 2002 to 2005. Before that, Dr. Tom Chen held the roles of Senior Microbiologist, Research Fellow, and Senior Investigation in drug discovery and development programs at Merck Research Laboratories between 1981 and 2001.
Dr. Tom Chen received a Ph.D. in Medicinal Chemistry from Purdue University, and a B.S. in Chemistry from National Tsing Hua University, Taiwan.